Table 1.
Patient characteristics and MK-1775 sensitivity for primary AML patient samples
| Patient | Gender | Age (year) | Disease status | FAB subtype | WBC (×10 3 /μL) | Blast purity (%) | Cytogenetics | MK-1775 IC 50 (nM) |
|---|---|---|---|---|---|---|---|---|
| AML#0 |
Female |
13 |
At diagnosis |
M2 |
39.9 |
79 |
46, XX, t(8;21)(q22;q22) |
5996.5 |
| AML#1 |
Female |
50 |
At diagnosis |
M4 |
22.66 |
52 |
46, XX, del(5q), add(12p) |
2448.5 |
| AML#2 |
Male |
20 |
At diagnosis |
M2 |
23.55 |
42 |
45, X, -Y, t(8;21)(q22;q22) |
3204.0 |
| AML#3 |
Male |
4 |
At diagnosis |
M3 |
4.71 |
75 |
46, XY, t(15;17)(q22;q21) |
461.0 |
| AML#4 |
Male |
55 |
At relapse |
M2 |
5.64 |
14 |
46, XY, t(8;21)(q22;q22) |
844.0 |
| AML#5 |
Female |
57 |
At relapse |
M2 |
22.16 |
70 |
46, XX |
948.3 |
| AML#6 |
Male |
60 |
At diagnosis |
M3 |
1.83 |
86 |
46, XY, t(15;17)(q22;q21) |
233.7 |
| AML#7 |
Female |
53 |
At relapse |
M4 |
3.87 |
36 |
46, XX |
325.0 |
| AML#8 |
Male |
55 |
At diagnosis |
M2 |
3.87 |
32 |
46, XY |
887.9 |
| AML#9 |
Female |
35 |
At relapse |
M5 |
17.71 |
87 |
47, XX, +10, t(16;21)(p11;q22), add(11p) |
744.4 |
| AML#10 |
Male |
23 |
At diagnosis |
M2 |
25.89 |
53 |
46, XY, del(9q) |
439.7 |
| AML#11 |
Female |
43 |
At diagnosis |
M2 |
25.12 |
91 |
46, XX |
411.3 |
| AML#12 |
Male |
6 |
At diagnosis |
M3 |
93.99 |
85 |
46, XY, t(15;17)(q22;q21) |
277.5 |
| AML#13 |
Male |
52 |
At diagnosis |
M2 |
1.65 |
27 |
46, XY, t(11;15;17)(q25;q15;q21) |
3579.5 |
| AML#14 |
Female |
18 |
At diagnosis |
M3 |
1.62 |
64 |
46, XX |
9113 |
| AML#15 |
Female |
63 |
At diagnosis |
M2 |
0.6 |
23 |
46, XX |
344.1 |
| AML#16 |
Male |
38 |
At diagnosis |
M3 |
2.27 |
90 |
46, XY, t(15;17)(q22;q21) |
216.9 |
| AML#17 |
Female |
45 |
At diagnosis |
M4 |
1.52 |
36 |
46, XX |
3473.0 |
| AML#18 |
Female |
19 |
At relapse |
M2 |
21.55 |
52 |
46, XX, t(8;21)(q22;q22) |
1187.0 |
| AML#19 |
Male |
4 |
At diagnosis |
M4 |
77.32 |
41 |
46, XY |
5587.0 |
| AML#21 |
Male |
42 |
At diagnosis |
M4 |
10.60 |
51 |
46, XY/44, XY, -17, -19, (11q-?) |
1176.0 |
| AML#22 |
Female |
47 |
At diagnosis |
M5 |
244.53 |
80 |
46, XX |
1255.0 |
| AML#23 |
Male |
60 |
At diagnosis |
M5 |
2.10 |
81 |
46, XY, +2, +8, I(12)(q10) |
1480.0 |
| AML#25 |
Female |
12 |
At diagnosis |
M3 |
5.11 |
88 |
46, XX, t(15;17)(q22;q21) |
615.1 |
| AML#26 |
Male |
59 |
At diagnosis |
M2 |
129.98 |
81 |
46, XY |
5868.0 |
| AML#27 |
Female |
41 |
At relapse |
M4 |
40.20 |
24 |
47, XX,del(5q),+8,t(15;18)(q12,q23) |
6384.0 |
| AML#29 |
Male |
9 |
At diagnosis |
M4 |
68.14 |
31 |
46, XY, t(6;9)(p22;q34) |
880.4 |
| AML#31 |
Male |
17 |
At diagnosis |
M2 |
12.94 |
69 |
46, XY |
453.7 |
| AML#32 | Female | 76 | At diagnosis | M5 | 13.93 | 85 | 46, XX | 2888.0 |